ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 2799 • 2017 ACR/ARHP Annual Meeting

    Efficacy, Safety and Immunogenicity in Randomized, Double-Blind (DB) and Open-Label Extension (OLE) Studies Comparing FKB327, an Adalimumab Biosimilar, with the Adalimumab Reference Product (Humira®; RP) in Patients (pts) with Active Rheumatoid Arthritis (RA)

    Mark C. Genovese1, Josephine Glover2, Nobuhito Matsunaga3, Diane Chisholm4 and Rieke Alten5, 1Stanford University Medical Center, Palo Alto, CA, 2Coephycient Pharmaceutical Consultancy, Guildford, United Kingdom, 3Fujifilm Kyowa Kirin Biologics, Chiyoda-ku, Tokyo, Japan, 4Fujifilm Kyowa Kirin Biologics, Galashiels, United Kingdom, 5University Medicine Berlin, Berlin, Germany

    Background/Purpose: FKB327 is a proposed biosimilar of the adalimumab RP. A randomized, DB, Phase 3 study (NCT02260791) compared the efficacy, safety, pharmacokinetics (PK) and immunogenicity…
  • Abstract Number: 287 • 2017 ACR/ARHP Annual Meeting

    Anti-TNF Agents Induce Alternative Macrophages

    Yannick Degboé1, Benjamin Rauwel2, Michel Baron2, Jean Frédéric Boyer2, Alain Cantagrel2, Arnaud Constantin3 and Jean-Luc Davignon2, 1Centre de Physiopathologie Toulouse Purpan, INSERM UMR 1043, Toulouse, France, 2CPTP, INSERM UMR 1043, Toulouse, France, 3Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France

    Background/Purpose: Macrophages contribute to the pathogenesis of rheumatoid arthritis (RA). They can display various states of activation or « polarization », characterized by distinct functions…
  • Abstract Number: 1527 • 2017 ACR/ARHP Annual Meeting

    Do TNF Inhibitors Alter the Natural History of Ankylosing Spondylitis By Impacting the Incidence and Prevalence of Comorbidities and Extra-Articular Manifestations?

    Atul A. Deodhar1, Kevin Winthrop2, Benjamin Chan2, Sarah A. R. Siegel2, Lisa Pisenti3, Jeffrey Stark3, Robert Y. Suruki4, Rhonda L. Bohn4, Huifeng Yun5, Lang Chen5 and Jeffrey R. Curtis5, 1Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 2Oregon Health & Science University, Portland, OR, 3UCB Pharma, Smyrna, GA, 4UCB Pharma, Raleigh, NC, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Treatment with TNF inhibitors (TNFi) has led to a reduction in signs and symptoms, and improvement in physical function and quality of life in…
  • Abstract Number: 2858 • 2017 ACR/ARHP Annual Meeting

    Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy

    Daniel J Lovell1, Sarah Ringold2 and P. Scott Eastman3, 1PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2Seattle Children's Hospital, Seattle, WA, 3Senior Director, New Product Development, Crescendo Bioscience, South San Francisco, CA

    Background/Purpose: More than 40% of children with polyarticular forms of Juvenile Idiopathic Arthritis (JIA) experience clinical inactive disease on medication (CR). No clinical variable or…
  • Abstract Number: 423 • 2017 ACR/ARHP Annual Meeting

    Refractory Pain in Spite of Inflammation Control after Start of Anti-TNF Therapy in RA: Observational Data from Southern Sweden

    Tor Olofsson1, Johan K Wallman2, Maria EC Schelin3, Anna Jöud4 and Jon Lampa5, 1Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, 2Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden, 3Lund University, Department of Clinical Sciences Lund, Oncology, Lund, Sweden, Lund, Sweden, 4Lund University, Department of Laboratory Medicine Lund, Division of Occupational and Environmental Medicine, Lund, Sweden, Lund, Sweden, 5Karolinska Institute, Department of Medicine, Rheumatology Unit, Stockholm, Sweden, Stockholm, Sweden

    Background/Purpose: Pain is a dominant and debilitating feature of RA, but while a lot of focus has been put on the occurrence and management of…
  • Abstract Number: 1530 • 2017 ACR/ARHP Annual Meeting

    Improvements in Sleep Problems and Pain in Patients with Active Ankylosing Spondylitis Treated with Intravenous Golimumab: 28-Week Results of the Phase III Trial

    Atul A. Deodhar1, John D. Reveille2, Eric K. H. Chan3, Steven Peterson4, Nan Li4, Elizabeth C. Hsia5, Lilianne Kim4, Kim Hung Lo4, Diane D. Harrison4 and Chenglong Han6, 1Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 2University of Texas McGovern Medical School, Houston, TX, 3Janssen Global Services, LLC, Raritan, NJ, 4Janssen Research & Development, LLC, Spring House, PA, 5Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, 6Janssen Global Services, LLC, Malvern, PA

    Background/Purpose: To investigate the effect of intravenously administered (IV) golimumab (GLM, 2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain (TBP), and…
  • Abstract Number: 2881 • 2017 ACR/ARHP Annual Meeting

    Pre-Existing Psoriasis Is Predictive for Clinical Relapse after Drug-Free Remission Induced By Therapy with Golimumab in Early Peripheral Spondyloarthritis

    Philippe Carron1, Gaëlle Varkas2, Thomas Renson3, Roos Colman4, Dirk Elewaut5 and Filip van Den Bosch6, 1Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 2Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium, 3Rheumatology, Ghent University Hospital, GENT, Belgium, 4Department of Public Health, Ghent University, Ghent, Belgium, Biostatistics Unit,Ghent University, Ghent, Belgium, Ghent, Belgium, 5VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, 6Rheumatology, Ghent University Hospital, Gent, Belgium

    Background/Purpose: The use of new treatment strategies in early stages of spondyloarthritis (SpA) makes it possible to achieve remission or low disease activity in more…
  • Abstract Number: 543 • 2017 ACR/ARHP Annual Meeting

    Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo

    I Mercedes-Núñez, E Tejada-Reyes, Y Cruz-Rojas, E Rodríguez-Bautista, R Munoz-Louis, V Rosario, R Peña-Blanco, T Valdez-Lorie and R Alba-Fériz, Rheumatology, Hospital Docente Padre Billini (HDPB), Santo Domingo, Dominican Republic

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune chronic disease with disability and deforms joints. After the introduction of biological therapies the prognosis of…
  • Abstract Number: 1531 • 2017 ACR/ARHP Annual Meeting

    Effects of Intravenous Golimumab on Patient-Reported Outcomes in Active Ankylosing Spondylitis: 28-Week Results of the Phase 3 Trial

    John D. Reveille1, Atul A. Deodhar2, Eric K.H. Chan3, Steven Peterson4, Nan Li4, Elizabeth C. Hsia5, Lilianne Kim4, Kim Hung Lo4, Diane D. Harrison4 and Chenglong Han6, 1University of Texas McGovern Medical School, Houston, TX, 2Division of Arthritis & Rheumatic Diseases OP09, Oregon Health & Science University, Portland, OR, 3Janssen Global Services, LLC, Raritan, NJ, 4Janssen Research & Development, LLC, Spring House, PA, 5Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, 6Janssen Global Services, LLC, Malvern, PA

     Background/Purpose: To evaluate patient-reported outcomes (PRO) of physical functioning, mental health functioning, health state, and health-related quality of life (HRQoL) in patients (pts) with active…
  • Abstract Number: 2962 • 2017 ACR/ARHP Annual Meeting

    MRI Results Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

    Charles Peterfy1, Joel Kremer2, William F C Rigby3, Nora Singer4, Christine Birchwood5, Darcy Gill5, William Reiss5, Jinglan Pei5 and Margaret Michalska5, 1Spire Sciences, Inc., Boca Raton, FL, 2Albany Medical College, Albany, NY, 3Geisel School of Medicine at Dartmouth, Lebanon, NH, 4Case Western Reserve University School of Medicine, Cleveland, OH, 5Genentech, Inc., South San Francisco, CA

    Background/Purpose: Although previous studies have established the efficacy of tocilizumab (TCZ) initiated as monotherapy (MONO) for the treatment of rheumatoid arthritis (RA),1,2 changes in active…
  • Abstract Number: 80 • 2017 Pediatric Rheumatology Symposium

    Treatment of Blau Syndrome with Biologic Therapy: A Single Center Case Series of Seven Patients Over Two Decades

    Jennifer Rammel1, Patricia Rosillo1, Tiphanie Vogel2 and Marietta de Guzman3, 1Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, 2Department of Pediatrics, Division of Immunology, Allergy and Rheumatology and the Center for Human Immunology at Texas Children's Hospital., Baylor College of Medicine, Houston, TX, 3Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX

    Background/Purpose: Blau syndrome is a rare autoinflammatory granulomatous disease that presents with fever, arthritis, dermatitis and uveitis. It results from mutations in NOD2, an intracellular…
  • Abstract Number: 80 • 2016 ACR/ARHP Annual Meeting

    Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis

    Philip Mease1, Manish Mittal2, Martha Skup2, Matthew Davis3, Arijit Ganguli2, Scott Johnson3 and Michael Schiff4, 1Swedish Medical Center and University of Washington, Seattle, WA, 2AbbVie Inc., North Chicago, IL, 3Medicus Economics, LLC, Milton, MA, 4University of Colorado, Greenwood Village, CO

    Background/Purpose: Treatment abandonment (failure to start therapy after prescription) is common among patients (pts) prescribed specialty pharmaceuticals. AbbVie offers a pt support program (PSP) for…
  • Abstract Number: 619 • 2016 ACR/ARHP Annual Meeting

    Concomitant Treatment Use during Treatment with Golimumab in Patients with Rheumatoid Arthritis

    Philip Baer1, Mary Bell2, Boulos Haraoui3, Louis Bessette4, John Kelsall5, Maqbool Sheriff6, Emmanouil Rampakakis7, Eliofotisti Psaradellis8, Francois Nantel9, Allen J Lehman10, Brendan Osborne11, Cathy Tkaczyk11 and Karina Maslova10, 1Independent Rheumatology Practice, Scarborough, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of Montreal, Montreal, QC, Canada, 4Rheumatology, CHUL de Quebec, Quebec, QC, Canada, 5Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, 6Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 7JSS Medical Research, St-Laurent, QC, Canada, 8JSS Medical Research, Montreal, QC, Canada, 919 Green belt Dr, Janssen Inc., Toronto, ON, Canada, 10Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose:  Previous studies have shown that, when sustained good clinical response has been achieved with a biologic therapy, traditional disease-modifying anti-rheumatic drugs (DMARDs) and other…
  • Abstract Number: 1702 • 2016 ACR/ARHP Annual Meeting

    Baseline Patient Characteristics Associated with Response to Biologic Therapy in Patients with Psoriatic Arthritis Enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Philip J Mease1, Chitra Karki2, Mei Liu2, Arthur Kavanaugh3, Christopher T. Ritchlin4, Doquyen H. Huynh3, Renganayaki Pandurengan2, Jacqueline B. Palmer5 and Jeffrey D. Greenberg2,6, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Southborough, MA, 3University of California San Diego, La Jolla, CA, 4Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6New York University School of Medicine, New York, NY

    Background/Purpose: The objective of this analysis was to investigate differences in baseline demographic and clinical characteristics of patients with psoriatic arthritis (PsA) who responded to…
  • Abstract Number: 2626 • 2016 ACR/ARHP Annual Meeting

    Soluble CD206 Plasma Levels Decreases with Treatment and Reflects Anti-Tnfa Discontinuation in Rheumatoid Arthritis

    Line Dam Heftdal1,2, Kristian Stengaard-Pedersen2, Merete Lund Hetland3,4, Kim Hørslev-Petersen5, Peter Junker6, Mikkel Østergaard4,7, Malene Hvid8,9, Bent Deleuran2,8,9, Holger Jon Møller8,10 and Stinne Greisen2,9, 1Department of Biomedicine, Department of Biomedicine, Aarhus University, Aarhus, Denmark, 2Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, Copenhagen, Denmark, 5King Christian X's Hospital for Rheumatic Diseases,, University of Southern Denmark, Graasten, Denmark, 6Department of Rheumatology, Odense University Hospital, Odense, Denmark, 7Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, 8Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 9Department of Biomedicine, Aarhus University, Aarhus, Denmark, 10Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the synovial joints and infiltration by activated macrophages. TNFa is a central…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology